novo nordisk ozempic - Search News

News

Novo Nordisk, Ozempic

Ozempic maker Novo Nordisk has its worst day since Black Monday

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic and Wegovy.

24/7 Wall St. · 2d

Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its full-year sales and profit outlook for the second time this year. The announcement,

The New York Times · 2d

Ozempic Maker’s Stock Plunges 20% After Profit Warning

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a new chief executive, who highlighted the “urgency” of the moment.

Novo Nordisk Gave Up Its Weight-Loss Gains

Benzinga · 3d

Novo Nordisk Implodes After Wegovy Warning—Is The Weight-Loss Bubble Bursting?

Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.

Bloomberg on MSN · 5h

How Novo Nordisk Gave Up Its Weight-Loss Gains

For a while, Danish drugmaker Novo Nordisk A/S looked unstoppable. It was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat diabetes,

Hosted on MSN · 57m

Novo Nordisk shares dip further as Wegovy gains nearly erased

By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent losses that threaten to wipe out all the gains since the drugmaker launched its blockbuster weight-loss treatment Wegovy four years ago.

35m

Medicare and Medicaid move toward covering Ozempic and other weight loss drugs

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

18hon MSN

Why Novo Nordisk Stock Crumbled Again Today

Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...

Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

3don MSN

NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?

Partially as a result, Novo Nordisk stock has steadily declined since last summer. Over the past year, NVO shares are down ...

Novo Nordisk names new CEO amid share price slump and concerns over Wegovy, Ozempic sales

The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...

2don MSN

Novo Nordisk shares fall 20% after company names new CEO and lowers its financial outlook

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

1don MSN

Novo Nordisk Stock Drops Further on Bank of America Downgrade

U.S.-listed shares of Novo Nordisk fell sharply for a second straight day Wednesday, this time after Bank of America ...

3hon MSN

New tariffs could raise prices of Ozempic, Wegovy

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results